Introduction And Importance: Mondor Disease is superficial thrombophlebitis mostly located in the thoracic-abdominal wall, mid-upper arm, and penis. The disease can affect all people over 30 years old regardless of race, ethnicity but affects women more than men. The importance of this study case consists on being the first reported case of Mondor Disease in Albania.
Case Presentation: In this study, a case of superficial thrombophlebitis affecting the thoraco-epigastric veins in the right chest wall is reported. Evidence of a palpable cord in the inferior outer quadrant of the breast was noted. The patient, a 49-year-old female who has been in menopause from March of 2021, presented with chest pain ought to two months of exaggerated physical activity.
Clinical Discussion: A detailed subjective and objective examination was performed. All laboratory data, including tests for COVID-19, showed normal range value except ESR. For 2 weeks under treatment with Ibuprofen, the chest pain was subsided but the palpable cord in the chest wall was persistent.
Conclusion: Reviewing the literature and after the Color Doppler examination it has been concluded in this diagnose. It was difficult to determine the diagnosis because of no previous experience with such clinical case.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10958058 | PMC |
| http://dx.doi.org/10.1016/j.ijscr.2024.109493 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Association Between Periodontitis, Gingivitis, Tooth Loss and Stroke: An Umbrella Study with Meta-Analysis.
Brain Sci
December 2024
INSERM U955-E01, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil, 94010 Créteil, France.
Background: Cerebrovascular diseases (CVAs) have several risk factors that are categorized as modifiable and nonmodifiable. Periodontal diseases (PD) have a modifiable role in causing CVA, where several studies suggested direct or indirect correlations with systemic diseases. This study aims to summarize, evaluate and analyze all the evidence available in literature, to reach a better understanding of the relation between periodontitis, gingivitis, tooth loss and CVA.
View Article and Find Full Text PDFEffectiveness and safety of biosimilars in pediatric inflammatory bowel diseases: an observational longitudinal study on the French National Health Data System.
World J Pediatr
January 2025
EPI-PHARE, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), 143-147 Boulevard Anatole France, 93285, Saint-Denis, France.
Background: Data on biosimilar use in pediatric inflammatory bowel diseases (IBD) are scarce compared to the status of studies in adults, resulting in limitations in its treatment. We compared effectiveness and safety of biosimilars versus originators in this population.
Methods: We used data from the French National Health Data System to identify children (less than 18 years old at treatment initiation) initiating treatment with a biosimilar or the originator infliximab or adalimumab for Crohn's disease (CD) or ulcerative colitis (UC), from first biosimilar launch (January 2015 and October 2018, respectively) to 31 December 2022.
Need for Trial Design Change in Epidermal Necrolysis (Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis): Example of Cyclosporine.
J Invest Dermatol
January 2025
Department of Dermatology, Henri Mondor Hospital, Assitance Publique Hôpitaux de Paris (AP-HP), Créteil, France; French National Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France; Université Paris-Est Créteil (UPEC), Créteil, France.
In patients with transplant-eligible newly diagnosed multiple myeloma, induction therapy with a quadruplet regimen prior to autologous transplant is the standard of care. The phase III IFM2020-02-MIDAS study (NCT04934475) assessed a minimal residual disease (MRD)-driven consolidation and maintenance strategy following induction with isatuximab, carfilzomib, lenalidomide, and dexamethasone (IsaKRD). Here, we report safety and efficacy outcomes of six 28-day cycles of IsaKRD.
View Article and Find Full Text PDFCombination of Baricitinib and Phototherapy in Adults With Active Vitiligo: A Randomized Clinical Trial.
JAMA Dermatol
January 2025
CNRS, Immuno ConcEpT, UMR 5164, University Bordeaux, Bordeaux, France.
Importance: Vitiligo is a chronic autoimmune disorder leading to skin depigmentation and reduced quality of life (QOL). Patients with extensive and very active disease are the most difficult to treat.
Objective: To assess the efficacy and adverse events of baricitinib combined with narrowband UV-B in adults with severe, active, nonsegmental vitiligo.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!